胸主动脉腔内修复术中主动脉弓原位激光开窗术当代结局的系统评价
本系统评价与Meta分析纳入2013至2021年间8项研究共440例患者,评估原位激光开窗腔内主动脉修复(L-FEVAR)治疗主动脉弓病变的疗效与安全性。技术成功率为93.3%,内漏事件率为0.06(95%CI 0.04-0.09,P<0.001),主要分支通畅率96.6%,30天死亡率为2.0%。作者认为该技术对不适合开放手术或定制腔内治疗的患者可行、安全、有效,但现有证据多为单中心回顾性短期随访。
要点
- L-FEVAR技术成功率为93.3%,主要分支通畅率96.6%,次级通畅率97%。
- Meta分析内漏事件率为0.06(95%CI 0.04-0.09,P<0.001),无显著异质性(Q=7.91,P=0.34)。
- 汇总并发症率:内漏4.8%、卒中2.0%、脊髓缺血0.2%、逆行夹层0.9%、30天死亡2.0%、入路并发症0.4%。
核心结论
- 原位激光开窗是治疗不适合开放手术或定制腔内治疗患者主动脉弓疾病的可行、安全、有效方法。
- 可获得高技术成功率和优异的短期分支通畅率。
- 这些单中心系列显示有前景的短期结局,初步数据为开展更大规模长期多中心前瞻性研究提供了有力论据。
研究设计与样本
- 系统文献综述与Meta分析,遵循PRISMA和Cochrane指南,检索Google、PubMed和Scopus。
- 纳入2013至2021年间8项研究,排除病例报告和少于10例的系列,共440例患者(范围15-148)。
- 87.5%的研究为回顾性,中位随访12.5个月(范围10-42)。
- 因样本量小,内漏事件率的Meta分析采用固定效应模型。
主要发现
- 患者平均年龄61岁(范围53-68),男性占64%,均为有症状患者。
- 主动脉弓干预的主要指征为主动脉夹层。
- 单开窗最常见(68%),其次为三开窗(22%)和双开窗(9%)。
- 中位手术时间162分钟(范围53-252),中位住院时间10天(范围7-17)。
- 汇总并发症率:内漏4.8%、卒中2.0%、脊髓缺血0.2%、逆行夹层0.9%、30天死亡2.0%、入路并发症0.4%;抗血小板方案报告不充分。
关键数值与推荐
- L-FEVAR技术成功率为93.3%。
- 8项研究(n=440)Meta分析内漏事件率为0.06(95%CI 0.04-0.09,P<0.001),效应异质性无统计学显著性(Q=7.91,P=0.34)。
- 主要分支通畅率为96.6%,次级通畅率为97%。
临床怎么用
- 原文未据此给出推荐。
- 作者认为原位激光开窗是治疗不适合开放手术或定制腔内治疗患者主动脉弓疾病的可行、安全、有效方法。
- 作者认为这些初步数据为开展更大规模长期多中心前瞻性研究提供了有力论据。
局限性
- 大多数研究为回顾性(87.5%)。
- 中位随访时间较短,为12.5个月(范围10-42)。
- 这些为单中心系列,显示的是短期结局。
- 抗血小板方案在研究队列中报告不充分。
- 作者认为需要开展更大规模长期多中心前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In situ laser fenestrated endovascular aortic repair (L-FEVAR) is a novel and creative solution for complex aortic pathologies in the urgent and emergency setting. Outcomes of this technique, however, are poorly reported. We sought to evaluate the efficacy, safety, and outcomes of L-FEVAR in aortic arch pathologies. METHODS: A systematic literature review and analysis were conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses and Cochrane guidelines. A search was conducted using Google, PubMed, and Scopus to identify studies evaluating L-FEVAR. Two independent reviewers determined study inclusion. Case reports and series including < 10 patients were excluded. Reviewers also assessed the methodological quality and extracted data regarding outcomes. A meta-analysis of endoleak event rates was conducted using a fixed-effect model due to small sample size. RESULTS: Eight studies met inclusion criteria between 2013 and 2021. Most studies were retrospective (87.5%) with median follow-up duration of 12.5 months (range 10-42). There were 440 patients included (range 15-148), mostly men (64%). Mean age was 61 years (range 53-68). Included patients were all symptomatic with L-FEVAR being technically successful in 93.3% of cases. The main indication for aortic arch intervention was aortic dissection. Single fenestrations occurred most frequently (68%), followed by triple (22%) then double fenestrations (9%). Meta-analysis of 8 studies (n = 440) demonstrated an endoleak event rate of 0.06 (95% confidence interval 0.04-0.09, P < 0.001) with no observed statistically significant heterogeneity of effects (Q = 7.91, P = 0.34). The median operative time was 162 min (range 53-252) with median length of stay of 10 days (range 7-17). Primary branch patency was 96.6%. Secondary patency rate was 97%. Pooled complication rates such as endoleak occurred in 4.8%, stroke in 2.0%, spinal cord ischemia in 0.2%, retrograde dissection in 0.9%, and 30-day death in 2.0%. Access complications occurred in 0.4%. Antiplatelet regimen was poorly reported in the study cohort. CONCLUSIONS: In situ laser fenestration is a feasible, safe, and effective approach to treat aortic arch disease in patients who are unsuitable for open or custom-made endovascular means. High technical success and excellent short-term branch patency can be achieved. These single-institution series exhibit promising short-term outcomes. In a similar paradigm to investigational device exemptions studies for custom-made and physician modified endografts, these preliminary data make a persuasive argument for larger long-term multi-institutional prospective study of this promising technique.
引用
- Tish S, Chase JA, Scoville C, et al. A Systematic Review of Contemporary Outcomes from Aortic Arch In Situ Laser Fenestration During Thoracic Endovascular Aortic Repair. Ann Vasc Surg. 2023. PMID: 36642166. doi:10.1016/j.avsg.2023.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。